Stem definition | Drug id | CAS RN |
---|---|---|
anti-inflammatory, indometacin derivatives | 1440 | 53-86-1 |
Dose | Unit | Route |
---|---|---|
0.10 | g | O |
0.10 | g | P |
0.10 | g | R |
0.10 | g | O |
0.10 | g | R |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.00 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 15 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 7.99 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 99 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.10 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1.30 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.01 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.40 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
June 10, 1965 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Neck deformity | 167.68 | 12.36 | 49 | 14975 | 1805 | 46669233 |
Neck mass | 147.71 | 12.36 | 51 | 14973 | 3242 | 46667796 |
Bone density abnormal | 120.11 | 12.36 | 43 | 14981 | 3041 | 46667997 |
Disability | 100.75 | 12.36 | 54 | 14970 | 10113 | 46660925 |
Drug hypersensitivity | 98.76 | 12.36 | 232 | 14792 | 243593 | 46427445 |
Ankylosing spondylitis | 90.68 | 12.36 | 44 | 14980 | 6693 | 46664345 |
Oligohydramnios | 89.92 | 12.36 | 41 | 14983 | 5424 | 46665614 |
Premature baby | 69.90 | 12.36 | 53 | 14971 | 18059 | 46652979 |
Mood swings | 68.18 | 12.36 | 50 | 14974 | 16202 | 46654836 |
Neonatal disorder | 66.69 | 12.36 | 19 | 15005 | 638 | 46670400 |
Premature delivery | 58.69 | 12.36 | 52 | 14972 | 22017 | 46649021 |
Limb deformity | 47.05 | 12.36 | 23 | 15001 | 3553 | 46667485 |
Anti-cyclic citrullinated peptide antibody positive | 46.75 | 12.36 | 43 | 14981 | 19102 | 46651936 |
Exposure during pregnancy | 44.77 | 12.36 | 104 | 14920 | 108108 | 46562930 |
Death | 43.78 | 12.36 | 27 | 14997 | 335521 | 46335517 |
Joint stiffness | 40.93 | 12.36 | 47 | 14977 | 27061 | 46643977 |
Corneal perforation | 39.77 | 12.36 | 12 | 15012 | 494 | 46670544 |
Rheumatoid factor positive | 38.79 | 12.36 | 40 | 14984 | 20421 | 46650617 |
Maternal drugs affecting foetus | 37.70 | 12.36 | 23 | 15001 | 5495 | 46665543 |
Low birth weight baby | 32.96 | 12.36 | 21 | 15003 | 5413 | 46665625 |
Hypermobility syndrome | 32.33 | 12.36 | 11 | 15013 | 668 | 46670370 |
Drug ineffective | 31.37 | 12.36 | 344 | 14680 | 677494 | 45993544 |
Hypercholesterolaemia | 30.32 | 12.36 | 27 | 14997 | 11503 | 46659535 |
Oesophageal spasm | 29.84 | 12.36 | 14 | 15010 | 1975 | 46669063 |
Neonatal respiratory distress syndrome | 29.51 | 12.36 | 15 | 15009 | 2518 | 46668520 |
Joint swelling | 29.05 | 12.36 | 118 | 14906 | 165955 | 46505083 |
Serotonin syndrome | 28.45 | 12.36 | 37 | 14987 | 24183 | 46646855 |
Musculoskeletal stiffness | 27.03 | 12.36 | 81 | 14943 | 97912 | 46573126 |
Oesophageal pain | 26.58 | 12.36 | 14 | 15010 | 2529 | 46668509 |
Arthralgia | 26.42 | 12.36 | 204 | 14820 | 364399 | 46306639 |
Therapeutic product effect decreased | 26.39 | 12.36 | 72 | 14952 | 82529 | 46588509 |
Polyarthritis | 24.92 | 12.36 | 19 | 15005 | 6523 | 46664515 |
Serum ferritin decreased | 22.86 | 12.36 | 11 | 15013 | 1641 | 46669397 |
Grip strength decreased | 22.32 | 12.36 | 20 | 15004 | 8586 | 46662452 |
Hydrops foetalis | 21.94 | 12.36 | 7 | 15017 | 347 | 46670691 |
Adrenal suppression | 21.74 | 12.36 | 9 | 15015 | 942 | 46670096 |
Premature labour | 21.25 | 12.36 | 22 | 15002 | 11277 | 46659761 |
Patent ductus arteriosus | 21.15 | 12.36 | 14 | 15010 | 3848 | 46667190 |
Cerebral vasoconstriction | 21.02 | 12.36 | 9 | 15015 | 1024 | 46670014 |
Impaired work ability | 20.93 | 12.36 | 23 | 15001 | 12613 | 46658425 |
Ankle fracture | 20.28 | 12.36 | 25 | 14999 | 15486 | 46655552 |
Large intestinal ulcer haemorrhage | 19.70 | 12.36 | 5 | 15019 | 107 | 46670931 |
Maternal exposure during pregnancy | 19.63 | 12.36 | 75 | 14949 | 102474 | 46568564 |
Alpha tumour necrosis factor increased | 19.28 | 12.36 | 4 | 15020 | 33 | 46671005 |
Fine motor skill dysfunction | 19.27 | 12.36 | 13 | 15011 | 3687 | 46667351 |
Pain | 19.25 | 12.36 | 236 | 14788 | 476712 | 46194326 |
Endothelin increased | 19.17 | 12.36 | 4 | 15020 | 34 | 46671004 |
Chronic gastritis | 18.98 | 12.36 | 11 | 15013 | 2392 | 46668646 |
Treatment failure | 18.58 | 12.36 | 69 | 14955 | 93018 | 46578020 |
Hirsutism | 18.08 | 12.36 | 8 | 15016 | 986 | 46670052 |
Foetal exposure during pregnancy | 17.88 | 12.36 | 34 | 14990 | 30713 | 46640325 |
Apgar score low | 17.80 | 12.36 | 7 | 15017 | 642 | 46670396 |
Blood pressure fluctuation | 16.89 | 12.36 | 33 | 14991 | 30415 | 46640623 |
Neuralgia | 16.81 | 12.36 | 27 | 14997 | 21356 | 46649682 |
Dyspraxia | 16.71 | 12.36 | 5 | 15019 | 200 | 46670838 |
Visceral leishmaniasis | 16.41 | 12.36 | 6 | 15018 | 450 | 46670588 |
Nerve degeneration | 16.26 | 12.36 | 4 | 15020 | 75 | 46670963 |
Migraine | 15.76 | 12.36 | 54 | 14970 | 69972 | 46601066 |
Decreased vibratory sense | 15.23 | 12.36 | 5 | 15019 | 272 | 46670766 |
Corneal neovascularisation | 14.70 | 12.36 | 4 | 15020 | 113 | 46670925 |
Oliguria | 14.61 | 12.36 | 16 | 15008 | 8743 | 46662295 |
Catheter site bruise | 14.59 | 12.36 | 5 | 15019 | 310 | 46670728 |
Alkalosis | 14.53 | 12.36 | 5 | 15019 | 314 | 46670724 |
White blood cell analysis abnormal | 14.23 | 12.36 | 3 | 15021 | 27 | 46671011 |
Right ventricular hypertrophy | 14.13 | 12.36 | 6 | 15018 | 669 | 46670369 |
Mydriasis | 13.78 | 12.36 | 17 | 15007 | 10536 | 46660502 |
Bradycardia foetal | 13.73 | 12.36 | 5 | 15019 | 371 | 46670667 |
Lymphoedema | 13.11 | 12.36 | 15 | 15009 | 8597 | 46662441 |
Fibromatosis | 13.02 | 12.36 | 3 | 15021 | 42 | 46670996 |
Rheumatoid arthritis | 12.94 | 12.36 | 126 | 14898 | 240089 | 46430949 |
Premature rupture of membranes | 12.92 | 12.36 | 11 | 15013 | 4412 | 46666626 |
Bursitis | 12.87 | 12.36 | 23 | 15001 | 19819 | 46651219 |
Pulmonary valve incompetence | 12.85 | 12.36 | 7 | 15017 | 1351 | 46669687 |
Metabolic acidosis | 12.57 | 12.36 | 34 | 14990 | 38746 | 46632292 |
Atrial fibrillation | 12.57 | 12.36 | 9 | 15015 | 103581 | 46567457 |
Ocular toxicity | 12.53 | 12.36 | 5 | 15019 | 476 | 46670562 |
Gingival hypertrophy | 12.52 | 12.36 | 7 | 15017 | 1422 | 46669616 |
Myoglobin blood increased | 12.49 | 12.36 | 7 | 15017 | 1429 | 46669609 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Gout | 125.85 | 13.08 | 81 | 11820 | 17234 | 29923343 |
Ankylosing spondylitis | 98.48 | 13.08 | 44 | 11857 | 4490 | 29936087 |
Ductus arteriosus premature closure | 84.13 | 13.08 | 17 | 11884 | 95 | 29940482 |
Sacroiliitis | 49.77 | 13.08 | 17 | 11884 | 843 | 29939734 |
Juvenile idiopathic arthritis | 46.57 | 13.08 | 17 | 11884 | 1026 | 29939551 |
Drug hypersensitivity | 43.81 | 13.08 | 89 | 11812 | 68430 | 29872147 |
Hepatitis B virus test positive | 41.84 | 13.08 | 11 | 11890 | 218 | 29940359 |
Mast cell activation syndrome | 39.33 | 13.08 | 9 | 11892 | 97 | 29940480 |
Hypoaldosteronism | 39.21 | 13.08 | 10 | 11891 | 175 | 29940402 |
Drug ineffective | 35.73 | 13.08 | 244 | 11657 | 340143 | 29600434 |
Arthralgia | 34.19 | 13.08 | 125 | 11776 | 135666 | 29804911 |
Duodenal perforation | 33.76 | 13.08 | 14 | 11887 | 1190 | 29939387 |
Neonatal disorder | 33.72 | 13.08 | 13 | 11888 | 913 | 29939664 |
Exostosis | 32.31 | 13.08 | 19 | 11882 | 3436 | 29937141 |
Death | 31.45 | 13.08 | 59 | 11842 | 357224 | 29583353 |
Chest expansion decreased | 31.42 | 13.08 | 8 | 11893 | 139 | 29940438 |
Axial spondyloarthritis | 30.36 | 13.08 | 8 | 11893 | 160 | 29940417 |
Benign abdominal neoplasm | 29.53 | 13.08 | 7 | 11894 | 89 | 29940488 |
Gouty arthritis | 28.68 | 13.08 | 12 | 11889 | 1043 | 29939534 |
Premature baby | 25.02 | 13.08 | 32 | 11869 | 16659 | 29923918 |
Placental transfusion syndrome | 24.55 | 13.08 | 4 | 11897 | 4 | 29940573 |
Xanthelasma | 24.09 | 13.08 | 6 | 11895 | 95 | 29940482 |
Gastric haemorrhage | 22.42 | 13.08 | 23 | 11878 | 9444 | 29931133 |
Hydrops foetalis | 22.36 | 13.08 | 7 | 11894 | 263 | 29940314 |
Coarctation of the aorta | 22.13 | 13.08 | 8 | 11893 | 469 | 29940108 |
Gastrointestinal haemorrhage | 21.97 | 13.08 | 78 | 11823 | 83368 | 29857209 |
Caesarean section | 20.64 | 13.08 | 12 | 11889 | 2125 | 29938452 |
Tendon disorder | 19.84 | 13.08 | 12 | 11889 | 2284 | 29938293 |
Enthesopathy | 19.64 | 13.08 | 13 | 11888 | 2893 | 29937684 |
Ankle fracture | 19.20 | 13.08 | 14 | 11887 | 3637 | 29936940 |
Thoracic vertebral fracture | 19.19 | 13.08 | 10 | 11891 | 1430 | 29939147 |
Tricuspid valve incompetence | 18.72 | 13.08 | 20 | 11881 | 8603 | 29931974 |
Osteopenia | 18.27 | 13.08 | 15 | 11886 | 4633 | 29935944 |
Gastric ulcer | 18.12 | 13.08 | 26 | 11875 | 15095 | 29925482 |
Water intoxication | 18.11 | 13.08 | 7 | 11894 | 495 | 29940082 |
Gastric bypass | 18.04 | 13.08 | 6 | 11895 | 274 | 29940303 |
Joint swelling | 18.00 | 13.08 | 50 | 11851 | 46896 | 29893681 |
Drug tolerance | 17.91 | 13.08 | 11 | 11890 | 2151 | 29938426 |
Procedural vomiting | 17.69 | 13.08 | 5 | 11896 | 131 | 29940446 |
Joint range of motion decreased | 17.21 | 13.08 | 16 | 11885 | 5829 | 29934748 |
Arthritis | 17.14 | 13.08 | 33 | 11868 | 24368 | 29916209 |
Therapeutic product effect incomplete | 17.09 | 13.08 | 40 | 11861 | 33794 | 29906783 |
Pulmonary sarcoidosis | 17.06 | 13.08 | 7 | 11894 | 579 | 29939998 |
Synovitis | 16.66 | 13.08 | 20 | 11881 | 9763 | 29930814 |
Iridocyclitis | 16.56 | 13.08 | 9 | 11892 | 1400 | 29939177 |
Joint space narrowing | 16.52 | 13.08 | 4 | 11897 | 56 | 29940521 |
Duodenal ulcer | 16.47 | 13.08 | 20 | 11881 | 9881 | 29930696 |
Myofascial pain syndrome | 16.47 | 13.08 | 6 | 11895 | 360 | 29940217 |
Burns second degree | 16.42 | 13.08 | 6 | 11895 | 363 | 29940214 |
Patent ductus arteriosus | 16.32 | 13.08 | 12 | 11889 | 3157 | 29937420 |
Sensitivity to weather change | 16.29 | 13.08 | 9 | 11892 | 1445 | 29939132 |
Stillbirth | 16.04 | 13.08 | 5 | 11896 | 185 | 29940392 |
Tobacco abuse | 15.92 | 13.08 | 6 | 11895 | 396 | 29940181 |
Osteoarthritis | 15.66 | 13.08 | 27 | 11874 | 18322 | 29922255 |
Sinusitis aspergillus | 15.63 | 13.08 | 4 | 11897 | 71 | 29940506 |
Intraventricular haemorrhage neonatal | 15.55 | 13.08 | 5 | 11896 | 205 | 29940372 |
Foot fracture | 15.44 | 13.08 | 13 | 11888 | 4159 | 29936418 |
Intracranial pressure increased | 15.29 | 13.08 | 12 | 11889 | 3478 | 29937099 |
Oromandibular dystonia | 15.07 | 13.08 | 6 | 11895 | 459 | 29940118 |
Melaena | 14.93 | 13.08 | 37 | 11864 | 32400 | 29908177 |
Adulterated product | 14.26 | 13.08 | 3 | 11898 | 21 | 29940556 |
Psoriasis | 14.10 | 13.08 | 43 | 11858 | 42463 | 29898114 |
Foetal distress syndrome | 13.54 | 13.08 | 7 | 11894 | 984 | 29939593 |
Physical deconditioning | 13.26 | 13.08 | 6 | 11895 | 630 | 29939947 |
Cardiomegaly | 13.24 | 13.08 | 22 | 11879 | 14487 | 29926090 |
Source | Code | Description |
---|---|---|
ATC | C01EB03 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY OTHER CARDIAC PREPARATIONS Other cardiac preparations |
ATC | M01AB01 | MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Acetic acid derivatives and related substances |
ATC | M02AA23 | MUSCULO-SKELETAL SYSTEM TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN Antiinflammatory preparations, non-steroids for topical use |
ATC | S01BC01 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFLAMMATORY AGENTS Antiinflammatory agents, non-steroids |
ATC | M01AB51 | MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Acetic acid derivatives and related substances |
ATC | S01CC02 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION Antiinflammatory agents, non-steroids and antiinfectives in combination |
FDA CS | M0001335 | Anti-Inflammatory Agents, Non-Steroidal |
FDA MoA | N0000000160 | Cyclooxygenase Inhibitors |
FDA EPC | N0000175722 | Nonsteroidal Anti-inflammatory Drug |
MeSH PA | D000700 | Analgesics |
MeSH PA | D018712 | Analgesics, Non-Narcotic |
MeSH PA | D000893 | Anti-Inflammatory Agents |
MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
MeSH PA | D018501 | Antirheumatic Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D016861 | Cyclooxygenase Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D006074 | Gout Suppressants |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D012102 | Reproductive Control Agents |
MeSH PA | D018689 | Sensory System Agents |
MeSH PA | D015149 | Tocolytic Agents |
CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory drugs |
CHEBI has role | CHEBI:35544 | cyclooxygenase inhibitors |
CHEBI has role | CHEBI:35703 | xenobiotic |
CHEBI has role | CHEBI:35845 | gout suppressants |
CHEBI has role | CHEBI:49103 | drug metabolites |
CHEBI has role | CHEBI:76206 | xenobiotic metabolites |
CHEBI has role | CHEBI:78298 | environmental contaminants |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Ankylosing spondylitis | indication | 9631008 | DOID:7147 |
Tendinitis | indication | 34840004 | DOID:971 |
Tenosynovitis | indication | 67801009 | DOID:970 |
Rheumatoid arthritis | indication | 69896004 | DOID:7148 |
Patent ductus arteriosus | indication | 83330001 | DOID:13832 |
Bursitis | indication | 84017003 | DOID:2965 |
Gout | indication | 90560007 | DOID:13189 |
Bursitis of shoulder | indication | 239961006 | |
Osteoarthritis | indication | 396275006 | |
Synovitis | indication | 416209007 | DOID:2703 |
Shoulder Tendonitis | indication | ||
Pericarditis | off-label use | 3238004 | DOID:1787 |
Premature labor | off-label use | 6383007 | |
Renal colic | off-label use | 7093002 | |
Pseudoprimary hyperaldosteronism | off-label use | 71275003 | |
Nephrogenic diabetes insipidus | off-label use | 111395007 | DOID:12387 |
Dysmenorrhea | off-label use | 266599000 | |
Fever | off-label use | 386661006 | |
Twin reversal arterial perfusion syndrome | off-label use | 417006004 | |
Necrotizing enterocolitis in fetus OR newborn | contraindication | 2707005 | |
Proctitis | contraindication | 3951002 | DOID:3127 |
Acute hemorrhage | contraindication | 8573003 | |
Rectal hemorrhage | contraindication | 12063002 | |
Hyperkalemia | contraindication | 14140009 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Parkinsonism | contraindication | 32798002 | |
Dehydration | contraindication | 34095006 | |
Depressive disorder | contraindication | 35489007 | |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Gastrointestinal ulcer | contraindication | 40845000 | |
Chronic heart failure | contraindication | 48447003 | |
Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
Duodenal ulcer disease | contraindication | 51868009 | DOID:1724 |
Gastrointestinal perforation | contraindication | 51875005 | |
Stomatitis | contraindication | 61170000 | DOID:9637 |
Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Hemorrhoids | contraindication | 70153002 | DOID:9746 |
Corneal deposit | contraindication | 74460005 | DOID:11547 |
Gastrointestinal hemorrhage | contraindication | 74474003 | |
Heart failure | contraindication | 84114007 | DOID:6000 |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Bacterial infectious disease | contraindication | 87628006 | |
Hyponatremia | contraindication | 89627008 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Blurring of visual image | contraindication | 111516008 | |
Seizure disorder | contraindication | 128613002 | |
Liver function tests abnormal | contraindication | 166603001 | |
Asthma | contraindication | 195967001 | DOID:2841 |
Sepsis of the newborn | contraindication | 206376005 | |
Coronary artery bypass graft | contraindication | 232717009 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Esophageal dysmotility | contraindication | 266434009 | DOID:9192 |
Cerebral hemorrhage | contraindication | 274100004 | |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Malignant tumor of colon | contraindication | 363406005 | DOID:219 |
Cardiovascular event risk | contraindication | 395112001 | |
Gastric ulcer | contraindication | 397825006 | DOID:10808 |
Diverticular disease | contraindication | 397881000 | |
Smokes tobacco daily | contraindication | 449868002 | |
Psychiatric Disturbance | contraindication | ||
Intraventricular Hemorrhage In Newborn | contraindication | ||
Congenital Heart Defect Requiring Open Patent Ductus Arteriosus | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 4.45 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Prostaglandin G/H synthase 2 | Enzyme | INHIBITOR | IC50 | 6.33 | WOMBAT-PK | CHEMBL | |||
Prostaglandin G/H synthase 1 | Enzyme | INHIBITOR | IC50 | 7.21 | WOMBAT-PK | CHEMBL | |||
Prostaglandin D2 receptor 2 | GPCR | Ki | 6.53 | WOMBAT-PK | |||||
Aldo-keto reductase family 1 member C3 | Enzyme | IC50 | 7 | CHEMBL | |||||
Interleukin-8 | Cytokine | IC50 | 7.30 | CHEMBL | |||||
Prostaglandin E synthase | Enzyme | IC50 | 4.39 | CHEMBL | |||||
Aldo-keto reductase family 1 member C4 | Enzyme | IC50 | 4.27 | CHEMBL | |||||
Androgen receptor | Nuclear hormone receptor | EC50 | 9.85 | CHEMBL | |||||
Multidrug resistance-associated protein 1 | Transporter | IC50 | 4.92 | CHEMBL | |||||
Aldo-keto reductase family 1 member C2 | Enzyme | IC50 | 4.44 | CHEMBL | |||||
Dehydrogenase/reductase SDR family member 9 | Enzyme | IC50 | 4.85 | CHEMBL | |||||
Lactoylglutathione lyase | Enzyme | Ki | 4.74 | CHEMBL | |||||
Aldose reductase | Enzyme | IC50 | 5.22 | CHEMBL | |||||
Potassium voltage-gated channel subfamily A member 7 | Ion channel | Ki | 7.50 | WOMBAT-PK | |||||
Multidrug resistance protein 1 | Transporter | IC50 | 4.49 | CHEMBL | |||||
Prostaglandin E2 receptor EP2 subtype | GPCR | Ki | 7.69 | PDSP | |||||
Peroxisome proliferator-activated receptor gamma | Nuclear hormone receptor | AGONIST | Kd | 7.38 | IUPHAR | ||||
Aldose reductase | Enzyme | IC50 | 5.44 | DRUG MATRIX | |||||
Aldose reductase | Enzyme | IC50 | 5.30 | CHEMBL | |||||
Prostaglandin G/H synthase (cyclooxygenase) | Enzyme | IC50 | 6.82 | CHEMBL | |||||
Prostaglandin G/H synthase 1 | Enzyme | Ki | 5.10 | CHEMBL | |||||
Prostaglandin-H2 D-isomerase | Enzyme | IC50 | 6.30 | CHEMBL | |||||
Prostaglandin G/H synthase 2 | Enzyme | IC50 | 6.47 | CHEMBL | |||||
Prostaglandin G/H synthase 2 | Enzyme | IC50 | 8.19 | CHEMBL | |||||
Prostaglandin G/H synthase 1 | Enzyme | IC50 | 8.70 | CHEMBL | |||||
Cyclooxygenase | Enzyme | IC50 | 7 | CHEMBL | |||||
Prostaglandin G/H synthase 2 | Enzyme | IC50 | 8 | CHEMBL | |||||
Cyclooxygenase | Enzyme | IC50 | 6.37 | CHEMBL | |||||
Prostaglandin G/H synthase 1 | Enzyme | IC50 | 8.22 | CHEMBL | |||||
Prostaglandin G/H synthase 1 | Enzyme | IC50 | 8.39 | CHEMBL | |||||
Nitric oxide synthase, inducible | Enzyme | IC50 | 4.70 | CHEMBL | |||||
Prostaglandin D2 receptor 2 | Unclassified | AGONIST | Ki | 6 | IUPHAR |
ID | Source |
---|---|
D00141 | KEGG_DRUG |
74252-25-8 | SECONDARY_CAS_RN |
4017890 | VANDF |
4017891 | VANDF |
C0700798 | UMLSCUI |
CHEBI:49662 | CHEBI |
IMN | PDB_CHEM_ID |
CHEMBL6 | ChEMBL_ID |
CHEMBL3989410 | ChEMBL_ID |
DB00328 | DRUGBANK_ID |
D007213 | MESH_DESCRIPTOR_UI |
1909 | IUPHAR_LIGAND_ID |
1524 | INN_ID |
XXE1CET956 | UNII |
3715 | PUBCHEM_CID |
1294612 | RXNORM |
2387 | MMSL |
2393 | MMSL |
4877 | MMSL |
d00039 | MMSL |
002373 | NDDF |
002374 | NDDF |
373513008 | SNOMEDCT_US |
60149003 | SNOMEDCT_US |
783274005 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Indomethacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1113 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 13 sections |
INDOMETHACIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0713-0176 | SUPPOSITORY | 50 mg | RECTAL | ANDA | 14 sections |
Indomethacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-083 | CAPSULE | 50 mg | ORAL | ANDA | 27 sections |
Indomethacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-919 | CAPSULE, EXTENDED RELEASE | 75 mg | ORAL | ANDA | 12 sections |
Indomethacin | Human Prescription Drug Label | 1 | 10544-935 | CAPSULE, EXTENDED RELEASE | 75 mg | ORAL | ANDA | 24 sections |
INDOMETHACIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-016 | CAPSULE, EXTENDED RELEASE | 75 mg | ORAL | ANDA | 28 sections |
INDOMETHACIN ER | HUMAN PRESCRIPTION DRUG LABEL | 1 | 12634-160 | CAPSULE | 75 mg | ORAL | ANDA | 14 sections |
INDOMETHACIN ER | HUMAN PRESCRIPTION DRUG LABEL | 1 | 12634-838 | CAPSULE | 75 mg | ORAL | ANDA | 14 sections |
INDOMETHACIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-130 | CAPSULE | 50 mg | ORAL | ANDA | 24 sections |
Indomethacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-522 | CAPSULE | 25 mg | ORAL | ANDA | 27 sections |
Indomethacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-523 | CAPSULE | 50 mg | ORAL | ANDA | 23 sections |
Indomethacin | Human Prescription Drug Label | 1 | 31722-542 | CAPSULE | 25 mg | ORAL | ANDA | 27 sections |
Indomethacin | Human Prescription Drug Label | 1 | 31722-543 | CAPSULE | 50 mg | ORAL | ANDA | 27 sections |
Indomethacin | Human Prescription Drug Label | 1 | 31722-565 | CAPSULE, EXTENDED RELEASE | 75 mg | ORAL | ANDA | 24 sections |
Indomethacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35356-697 | CAPSULE | 50 mg | ORAL | ANDA | 27 sections |
INDOCIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42211-101 | SUSPENSION | 25 mg | ORAL | NDA | 28 sections |
INDOCIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42211-102 | SUPPOSITORY | 50 mg | RECTAL | ANDA | 29 sections |
Tivorbex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42211-201 | CAPSULE | 20 mg | ORAL | NDA | 28 sections |
Tivorbex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42211-202 | CAPSULE | 40 mg | ORAL | NDA | 28 sections |
Indomethacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-081 | CAPSULE | 50 mg | ORAL | ANDA | 27 sections |
INDOMETHACIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-237 | CAPSULE | 25 mg | ORAL | ANDA | 25 sections |
Indomethacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-368 | CAPSULE | 25 mg | ORAL | ANDA | 29 sections |
Indomethacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-773 | CAPSULE | 25 mg | ORAL | ANDA | 27 sections |
Indomethacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-777 | CAPSULE | 50 mg | ORAL | ANDA | 27 sections |
Indomethacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-929 | CAPSULE | 50 mg | ORAL | ANDA | 29 sections |
Indomethacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-930 | CAPSULE | 50 mg | ORAL | ANDA | 29 sections |
Indomethacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49349-776 | CAPSULE | 50 mg | ORAL | ANDA | 24 sections |
Indomethacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49999-371 | CAPSULE, EXTENDED RELEASE | 75 mg | ORAL | ANDA | 12 sections |
Indomethacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0051 | CAPSULE | 50 mg | ORAL | ANDA | 32 sections |
Indomethacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0053 | CAPSULE | 25 mg | ORAL | ANDA | 32 sections |